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Allosteric modulation of receptor function
Structure activity relationships
Aims: Endothelin-1 (ET-1) and endothelin-2 (ET-2; Trp6Leu7ET-1) are expressed by different cell types, but are
considered to display identical pharmacological properties on endothelin receptors. We studied agonist-
dependent aspects of endothelinA (ETA)-receptor function and the importance of amino acids 6 and 7 of ET-1
and ET-2 in this respect.
Mainmethods:Weused isolated ratmesenteric resistance arteries inwiremyographs, in a setting thatminimizes
inﬂuences of endothelium and sensorimotor nerves, to study arterial smooth muscle ETA-receptor-mediated
vasomotor responses, to ET-1, ET-2 and chimeras thereof (Trp6ET-1 and Leu7ET-1).
Key ﬁndings: ET-1 and ET-2 cause arterial contractions with comparable sensitivities and maximal responses.
BQ123 (ETA-antagonist) reduces sensitivity to ET-1 more potently than that to ET-2 (pKB: 7.1±0.2 versus
5.6±0.4). However, 1 μM BQ123 relaxes maximal contractile responses to ET-2 more markedly than those to
ET-1. Leu7ET-1 is a contractile agonist with lower potency and similar maximal effect compared to ET-1 and
greater sensitivity to BQ123 than ET-2. Up to 256 nM Trp6ET-1 did not cause contraction and did not antagonize
arterial responses to ET-1.
Signiﬁcance: Arterial smooth muscle ETA-receptor function displays agonist-dependent aspects. This involves
roles of amino acids on position 6 and 7 of the endothelin sequence. Agonist-dependent pathologiesmay beneﬁt
from the design of speciﬁc, agonist-selective ET-receptor antagonists.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Evolution left homo sapiens with three distinct potent vasoactive
members of the endothelin family; endothelin-1 (ET-1), endothelin-
2 (ET-2) and endothelin-3 (ET-3) (Braasch et al., 2009; Masaki,
2004). The biological effects of these 21 amino acid bicyclic peptides
are mediated by two distantly related 7 transmembrane domain re-
ceptors (7TMRs): endothelinA(ETA)- and endothelinB (ETB)-receptors
(Braasch et al., 2009; Davenport, 2002; Masaki, 2004). Binding to ETB-
receptors requires the 6 amino acid C-terminus, which is identical for
all three ETs, making them equipotent at this receptor (Mihara and
Fujimoto, 1992). The 15 amino acid N-terminal loop, with disulﬁde
bonds between Cys1 and Cys15 and between Cys3 and Cys11, deter-
mines selectivity for the ETA-receptor (Arai et al., 1990). Compared
to ET-1 and ET-2, ET-3 differs in 6 amino acids within the N-terminal
loop, distinguishing ET-3 as an ETB-selective ligand (Davenport,
2002; Sakurai et al., 1992).
ET-1 and ET-2 were reported to be non-selective ET-receptor
agonists. Their amino acid sequences differ only at positions 6 and 7
within the N-terminal loop. They bind to ETA and ETB with equallogy, Cardiovascular Research
16, 6200MD Maastricht, The
49.
.R. De Mey).
-NC-ND license.afﬁnities and their pharmacological properties were proposed to be
identical (Davenport, 2002; Masaki, 2004). However, ET-1 and ET-2
are expressed by different cell types, restricting their paracrine and
autocrine function to distinct tissues (Levin, 1995). ET-1 is mainly
found in the cardiovascular system where it causes, amongst other
effects, long-lasting vasoconstriction mediated by tight binding to
ETA-receptors (Hynynen and Khalil, 2006; Meens et al., 2010, 2011;
Yanagisawa et al., 1988). ET-2 is mainly found in the gastrointestinal
tract and the urogenital system (Levin, 1995). Via ETA-receptors, ET-2
can modulate immune cell function (Takizawa et al., 2005) and ovu-
lation (Ko et al., 2006).
ET-1 and ET-2 are expressed at different developmental stages in
the embryo and in different cell types and organ systems in the
adult (Braasch et al., 2009). While ET-1 is intimately involved in the
cardiovascular system (Hynynen and Khalil, 2006), ET-2 seems to
have selective functions in for instance the ovaries (Ko et al., 2006;
Meidan and Levy, 2007). The pharmacological properties of ET-1
and ET-2 have been considered to be identical (Masaki, 2004). This
may be surprising because during the course of evolution other
endothelin isoforms were lost (Braasch et al., 2009). We therefore
compared both peptides beyond apparent afﬁnities and efﬁcacies.
Here we tested the hypothesis that ET-1 and ET-2 display distinct
ETA-receptor mediated pharmacological properties. We studied in-
hibitory effects of an antagonist of ETA-receptors (BQ123, (Ihara
et al., 1992)) on arterial responses to the two endogenous agonists.
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ET-1/ET-2 chimeras, one in whichwe substituted Leu6 of ET-1 for Trp6
of ET-2 (Trp6ET-1 (or Met7ET-2)) and another one in which we
substituted Met7 of ET-1 for Leu7 of ET-2 (Leu7ET-1 (or Leu6ET-2)).
Our observations indicate agonist-dependent modulation of ETA-
receptor function and marked effects of amino acids 6 and 7 of the
endothelin sequence in this respect.
Materials and methods
Experiments were performed in accordance with institutional
guidelines and were approved by the Ethics Committee on Experi-
mental Animal Welfare of the Maastricht University.
Solutions and compounds
BQ123 (Sigma Aldrich, Zwijndrecht, NL) and BQ788 (Peptides
International, Louisville, USA) were dissolved in DMSO. Capsaicin
(CAPS) and indomethacin (INDO) (Sigma Aldrich, Zwijndrecht, NL)
were dissolved in ethanol. Human ET-1, human ET-2, 4AlaET-1, Sarafo-
toxin 6c (S6c) (Bachem, Weil am Rhein, D), noradrenaline (NA) and
Nω(G)-nitro-L-arginine methyl ester (L-NAME) (Sigma Aldrich, Zwijn-
drecht, NL) were dissolved in Krebs Ringer bicarbonate buffer (KRB) con-
taining (in mM): NaCl: 118.5; KCl: 4.7; CaCl2: 2.5; MgSO4: 1.2; KH2PO4:
1.2; NaHCO3: 25.0; glucose: 5.5. The maximal solvent concentration
never exceeded 0.1% and did not signiﬁcantly modify arterial vasomotor
responses.
De novo synthesis of Trp6ET-1 and Leu7ET-1
Single batches of Trp6ET-1 and Leu7ET-1 were synthesized by
manual solid-phase peptide synthesis on 4-methylbenzhydrylamine
(MBHA) resin using the in situ neutralization/activation procedure
for tBoc-peptide synthesis as described (Schnolzer et al., 1992), but
using O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
hexaﬂuorophosphate (HCTU) instead of O-(Benzotriazol-1-yl)-N,N,N′,
N′-tetramethyluronium hexaﬂuorophosphate (HBTU) as a coupling
reagent. To allow controlled Cys3–Cys11 and Cys1–Cys15 disulﬁde for-
mationwithin ET peptides, two acetamidomethyl (Acm)-protected cys-
teines (1;15) were used that could selectively be deprotected during
folding, ensuring the correct folding of the N-terminal loop of the
peptide. The peptides were cleaved from the resin by treatment with
anhydrous hydroﬂuoric acid for 1 h at 0 °C, using 4 v-% p-cresol as a
scavenger. Following cleavage, the peptides were puriﬁed by prepara-
tive high-performance liquid chromatography (HPLC). Fractions con-
taining the desired product were identiﬁed by electrospray ionization
mass spectrometry, pooled and lyophilized.
Peptide folding
The peptides were folded by a two-step protocol. The ﬁrst disulﬁde
bond was formed stirring the puriﬁed peptide in 0.05 M Tris buffer pH
8.0, 3 M Gn HCl (0.2 mg/ml) for 72 h at 4 °C. For the second disulﬁde
bond the solution was adjusted to 10% AcOH, purged with nitrogen, and
Acm groups were removed by addition of 2 equivalents of iodine
(0.12 M in methanol). Reaction progress was monitored by analytical
HPLC and ESI-MS. Products were puriﬁed by semi-preparative HPLC and
lyophilized. Presence of two disulﬁde bonds in the peptides in solution
was checked by HPLC after completing the functional experiments.
Recording of vasomotor responses
Male, 16 weeks old Wistar Kyoto rats (Charles River, Maastricht,
The Netherlands) were euthanized by CO2-inhalation. Second-order
branches of the superior mesenteric artery were isolated by dissection
in KRB at room temperature. To record isometric tension development,freshly isolated 2 mm long arterial segments were mounted in wire
myographs (DMT, Aarhus, DK) in which 5 ml KRB was maintained at
37 °C and aerated with 95% O2/5% CO2. The arterial segments were
stretched to the diameter at which the largest contractile response to
10 μMNAwas obtained (Meens et al., 2010, 2009). The optimal internal
diameter of the segments averaged 306±8 μmand contractile responses
to 10 μMNA averaged 3.9±0.1 N/m.
Arterial segments were pre-treated with 1 μM CAPS for 20 min
and were thereafter studied in the continuous presence of 100 μML-
NAME and 10 μM INDO. These interventions minimize the effects of
sensorimotor nerves and of the endothelium, which we have previ-
ously shown to express immunoreactive ETA- and ETB-receptors
(Meens et al., 2010, 2009).
Pharmacological protocols
Increasing concentrations of an endothelin isopeptide (cumulative
concentration–response curve, CCRC)were administered to resting arter-
ies to record contractile effects. The effect of ETB-receptor activation was
assessed using the ETB-agonists 4AlaET-1 (Saeki et al., 1991) and S6c
(Deng et al., 1995) and the ETB-antagonist BQ788 (Ishikawa et al., 1994).
Competition experiments
Using arterial segments in parallel, CCRCs for a putative agonist
were constructed in the absence and in the presence of 1 μM of an
antagonist. Effects of the antagonist on the position (ratio of EC50,
pKB) and on the height of the agonist CCRC (EMAX) were monitored.
Inhibition experiments
In arteriesmade to contract with an ET, we acutely applied the same
concentration of the antagonist as we used in the competition experi-
ments. Thereafter, we assessed the effect of removal of the receptor
ligands on contractility of the arterial segments as a measure for the
remaining receptor activation. Because endothelins cause long-lasting
arterial contractile effects (Meens et al., 2010; Yanagisawa et al.,
1988), comparable inhibition experiments were performed on
agonist-initiated contractions, where we removed the free agonist
before assessing the inhibitory effects of the antagonist.
Only one set of experiments was performed in one set of arterial
segments, i.e. distinct pharmacological protocols were not performed
in series in the same set of arterial segments. Experiments comparing
BQ123-induced inhibition of ET-1- and ET-2-induced contractile
effects were analyzed in comparison to control curves within the
same rat and not to curves obtained in rats used to compare the
various endothelinergic peptides.
Data analysis and statistics
Data are shown asmean±SEM. Contractile responses are expressed
as percentage of themaximal contractile response to NA observed prior
to the administration of any pharmacological inhibitor (NAMAX). Indi-
vidual CCRC were ﬁtted to a non-linear regression curve and ED50 and
pKB values were calculated using GraphPad Prism 5.02. Data were
analyzed using one-way ANOVA (comparison of pD2, pKB and Emax) or
two-way ANOVA (comparison of CCRC). Bonferroni's post-hoc test
was used to comparemultiple groups. Pb0.05was considered to denote
statistical signiﬁcance.
Results
Vasomotor responses to ET-1 and ET-2
Nanomolar concentrations of ET-1 and ET-2 caused long-lasting
contractions in isolated rat mesenteric resistance arteries. When
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0.1 and 8.5±0.1, respectively) and the maximal effect (EMAX: 102±
5% vs. 99±10%) did not differ signiﬁcantly between both peptides
(Fig. 1A), in line with earlier ﬁndings (Bogoni et al., 1996; Saito et al.,
1991) and in addition their effects were equally persistent (Fig. 1D
and F). In contrast, the ETB-selective agonists S6c (Deng et al., 1995),
found in snake venom, and 4AlaET-1 (Saeki et al., 1991), a linear ana-
logue of ET-1 where the four Cys residues are replaced by Ala, did
not contract the isolated arteries at up to 1 μM (Fig. 1A) (Maguire
and Davenport, 1995). Furthermore, presence of 1 μM 4AlaET-1 or of
1 μM BQ788, an ETB-selective antagonist (Ishikawa et al., 1994),
tended to alter the sensitivity to ET-1 but this did not reach statistical
signiﬁcance (Fig. 1B). These ﬁndings indicate that ET-1 and ET-2 cause
seemingly similar ETA-receptor mediated arterial smooth muscle con-
tractions, although sensitivity to ET-2 in these 2nd order mesenteric
arterial side branches is rather variable in experiments performed in
sets of rats within a few weeks interval (Fig. 1A and E).Fig. 1. Vasomotor effects of isoforms and analogues of ET-1. ET-1 and ET-2 induce contracti
4AlaET-1 and S6c do not induce responses (A).Neither 4AlaET-1 nor the selective ETB-rece
Sensitivity to ET-1-induced contractions (C) and ET-2-induced contractions (E) are reduce
established, they are sustained following removal of BQ123 and ET-1 (D) or ET-2 (F).Effects of an ETA-antagonist
Presence of 1 μM of the ETA-selective antagonist BQ123 (Ihara
et al., 1992) reduced the sensitivities to ET-1 and ET-2 without signif-
icant alteration of their maximal contractile effects (Fig. 1C and E). In
contrast to earlier reports, where BQ123 inhibited ET-2-induced con-
tractions more effectively than ET-1-induced contractions in a prepa-
ration of either rings of the superior mesenteric artery or the perfused
mesenteric arterial bed (Donoso et al., 1996), the effect of the antag-
onist was observed to be more pronounced against ET-1 (11 fold
reduction of sensitivity) than against ET-2 (2 fold) in our preparation
using 2nd order mesenteric artery side branches and a different phar-
macological study protocol. As a consequence, the apparent afﬁnity of
BQ123 was 30 times higher against ET-1 (pKB: 7.1±0.2) than against
ET-2 (pKB: 5.6±0.4). Presence of BQ123 did on the other hand not
prevent the development of persistent long-lasting contractile effects
of ET-1 and ET-2 (Fig. 1D and F).ons with comparable afﬁnity and efﬁcacy, whereas the selective ETB-receptor agonists
ptor antagonist BQ788 signiﬁcantly alter the ET-1-induced contractile responses (B).
d in the presence of selective ETA-antagonist 1 μM BQ123. Once full contractions are
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to ET-1 or ET-2 of comparable amplitude, resulted in signiﬁcant relax-
ation (Fig. 2A and B). BQ123 relaxed ET-1-induced contractions by
43±7% but inhibited ET-2-induced effects to a signiﬁcantly larger
extent (92±1%). In both cases, the relaxing effect of BQ123 was
rapidly reversible as tonic contractions redeveloped within 1 to
2 min after ﬂushing both the ET and the antagonist from the organ
chamber content (Fig. 2A and B). Similarly, when contractile re-
sponses were initiated by an ET and then allowed to proceed in the
absence of free agonist, application of 1 μM BQ123 caused a reversible
relaxation (Fig. 2C and D). Again this relaxing effect was signiﬁcantly
smaller for ET-1- (56±1%, Fig. 2C) than for ET-2-initiated contrac-
tions (90±2%; Fig. 2D).
These observations with BQ123 indicate agonist-dependent mod-
ulation of arterial smooth muscle ETA-receptor function. We next
evaluated whether this could be attributed to one of the two amino
acids that differ between the sequences of ET-1 and ET-2.
De novo chimera synthesis
Two chimeras of ET-1/ET-2 were synthesized and studied. The
folded Leu7ET-1 (CSCSSL6L7DKECVYFCHLDIIW) had an observed
mass of 2472.2 Da, ﬁtting well between the calculated monoisotopic
mass (2472.1) and the average mass (2473.9) of the folded peptide.
The folded Trp6ET-1 (CSCSSW6M7DKECVYFCHLDIIW) peptide had
an observed mass of 2563.3 Da, ﬁtting well between the calculated
monoisotopic mass (2563.0) and the average mass (2565.0) of the
folded peptide. An observed mass difference of −144.2 Da between
reduced and folded peptide corresponded to the expected mass
reduction caused by the loss of 2 protons and 2 Acm groups due to
the formation of 2 disulﬁde bonds. The correct conformation of disul-
ﬁde bonds (Cys3-Cys11; Cys1–Cys15) was ensured by applying a two-
step disulﬁde formation procedure (see Material and Methods),
allowing the second disulﬁde bond between Cys1 and Cys15 to formFig. 2. Inhibitory effects of BQ123 on sustained and maintained contractions. 1 μM BQ123 r
removal (C) of free agonist. The BQ123-induced inhibitions were rapidly reversed upon re
BQ123 by approximately 90% in presence (B) or following removal (D) of free agonist. Again
* Pb0.05 vs control, # Pb0.05 vs BQ123 effect on ET-1.only after the ﬁrst disulﬁde bond between Cys3 and Cys11 was cor-
rectly formed.
Vasomotor effects of ET-1/ET-2 chimeras
Trp6ET-1 (0.25 to 256 nM) did not induce contractile responses
(Fig. 3A) and no contraction developed when the peptide was re-
moved from the organ chamber (Fig. 3B). Also, presence of 256 nM
Trp6ET-1 did not signiﬁcantly modify contractile responses to ET-1
(pD2: 8.3±0.3 and 8.4±0.1; EMAX: 102±5% and 97±7% in absence
and presence of Trp6ET-1, respectively). These indicate a particularly
low afﬁnity of Trp6ET-1 for arterial smooth muscle ETA-receptors.
Increasing concentrations of Leu7ET-1 caused contractile re-
sponses in rat mesenteric resistance arteries with a potency (pD2:
7.2±0.1) that was 10–20 times smaller than that of ET-1 but with a
similar maximum (Fig. 3C). As observed with ET-1 and ET-2, the arte-
rial contractile effect of Leu7ET-1 was long-lasting, i.e. it persisted
after washout of the free unbound analogue (Fig. 3D). Presence of
1 μM BQ123 prevented contractile responses to up to 256 nM
Leu7ET-1 (Fig. 3C). Availability of only limited amounts of Leu7ET-1
prevented estimation of the apparent afﬁnity of the antagonist in
this setting. However, comparison with Fig. 1 suggests that afﬁnity
of BQ123 versus Leu7ET-1 is larger than versus ET-2 (Trp6Leu7ET-1).
Also, it is noteworthy that while presence of BQ123 prevented
Leu7ET-1-induced contraction, a strong response developed rapidly
after washout of both ligands (Fig. 3D). This indicates tight binding
of Leu7ET-1 to ETA-receptors and inhibition of ETA-receptor activity
by BQ123.
Discussion
The main ﬁndings of this work are that i) not only ET-1, but also
ET-2 causes long-lasting arterial contractions, ii) arterial smoothmus-
cle ETA-receptors display agonist-dependent function, iii) BQ123 actseduces ET-1-induced contractions by approximately 50% in presence (A) or following
moval of antagonist and/or agonist. ET-2-induced contractions were reduced by 1 μM
, these BQ123-induced inhibitions were rapidly reversed upon removal of the ligand(s).
Fig. 3. Vasomotor responses to Trp6ET-1 and Leu7ET-1. Trp6ET-1 did not induce contractions up to 256 nM (A) and no contraction developed following removal of the putative
vasoactive compounds (B). Leu7ET-1 induced ETA-mediated contractions, which were, up to 256 nM, fully inhibited by 1 μM BQ123 (C). These contractions were sustained follow-
ing removal of free agonist (D) and developed following the removal of free vasoactive compounds (red lines).
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tion of a single amino acid in the N-terminal loop of ET-1 can have
profound pharmacological consequences. This may lead the way to
the development of agonist-selective ETA-receptor antagonists.
To study ETA-receptor function we used rat mesenteric resistance
arteries, which take part in the regulation of local and total peripheral
vascular resistance and in the development of hypertension
(Mulvany and Aalkjaer, 1990). We performed all experiments after
desensitization of peri-arterial sensorimotor nerves and during con-
tinuous inhibition of cyclo-oxygenases and NO-synthases. The selec-
tive ETB-receptor agonists 4AlaET-1 and S6c and the ETB-receptor
antagonist BQ788 were without effects, the latter not only versus
ET-1-induced contractions but also versus ET-2-induced contractions
(data not shown). ET-1 and ET-2 caused contractions and the sensi-
tivity to these non-selective ET-receptor agonists was reduced by
BQ123. These results indicate that the responses investigated are me-
diated by smooth muscle ETA-receptors (Davenport, 2002) and are
not modulated by endothelium, sensorimotor nerves or ETB-receptors
as we have previously proposed (Meens et al., 2010).
Not surprisingly, sensitivity and maximal responses to ET-1 and
ET-2 did not differ signiﬁcantly in arteries from the same animals.
The responses to both peptides were long-lasting. They persisted
after removal of free unbound agonist, in line with earlier ﬁndings
in different preparations (Saito et al., 1991), by a procedure that
abolishes arterial responses to other contractile stimuli within less
than 2 min (Meens et al., 2010), in line with earlier ﬁndings. For ET-
1 this has been attributed to tight binding of the peptide to ETA-
receptors (De Mey et al., 2011; Hilal-Dandan et al., 1997; Meens
et al., 2010). To us it seems fair to propose that, also for ET-2, the
rate of dissociation of the agonist/receptor complexes is particularly
slow although estimates of this parameter have not been reported
for this isopeptide yet. Our proposal is strengthened by the ﬁnding
that BQ123 caused reversible relaxations of ET-2-induced and ET-2-initiated contractions as previously reported for ET-1 (Meens et al.,
2010, 2011).
The cyclic pentapeptide and ETA-selective antagonist BQ123
(Ihara et al., 1992) reduced sensitivity and responses to both
endothelins. The antagonist, however, reduced the sensitivity to ET-
1 more markedly than that to ET-2. Conversely, the antagonist
reduced responses to ET-2 more markedly than those to ET-1. This
agonist-dependence and these different effects under resting and
activating conditions are not compatible with neutral competitive
antagonism but indicative of negative allosteric modulation of ETA-
receptor function (Christopoulos and Kenakin, 2002; De Mey et al.,
2011; Keov et al., 2011). In this view, BQ123 binds to ETA-receptors
at a site that is topographically distinct from the orthosteric binding
sites of ET-1 and ET-2. This binding of the modulator changes the con-
formation of the receptors and thereby alters their afﬁnities for the
orthosteric ligands. In addition the bound modulator reduces the in-
trinsic activity of the agonist/receptor complexes. Activation resulting
from tight binding of ET-2 to ETA-receptors was reduced to a larger
extent than that resulting from ET-1. Whether also some of the low
molecular weight non-peptidergic ET-receptor antagonists are nega-
tive allosteric modulators rather than neutral competitive antagonists
(De Mey et al., 2011) largely remains to be established. For bosentan,
however, it has been shown that its binding site does not fully coin-
cide with that of ET-1 on ETA-receptors (Breu et al., 1995) and ABT-
627 was shown to promote internalization of ETA-receptors (Chiou
et al., 2000); an effect that is not compatible with neutral competitive
antagonism.
To gain insight in the mechanism of agonist-dependence of ETA-
receptor function, we synthesized chimeras of ET-1 and ET-2. Chem-
ical analyses performed before and after the ex vivo experiments
demonstrated that both compounds remained intact and were of
the desired molecular weight. Leu7ET-1 behaved as a full ETA-agonist
but was less potent than ET-1 and ET-2. Presence of BQ123 reduced
612 M.G. Compeer et al. / Life Sciences 91 (2012) 607–612the sensitivity to Leu7ET-1 more markedly than that to ET-2
(Trp6Leu7ET-1). However, BQ123 reduces the intrinsic activity of
Leu7ET-1 rather than its afﬁnity for ETA-receptors. This suggestion is
based on the observation that while BQ123 prevented contractile
responses to the chimera, the antagonist did not prevent the develop-
ment of a strong contractile response when both unbound ligands
were removed. Apparently, Leu7ET-1 bound tightly to ETA-receptors
even in the presence of BQ123 and the antagonist inhibited the activ-
ity of the agonist/receptor complexes. The ﬁndings with Leu7ET-1
thus strengthen the notions of agonist-dependence of ETA-receptor
function and the allosteric properties of BQ123. Trp6ET-1, on the
other hand, displayed neither agonistic nor antagonistic properties
at concentrations at which even a low-afﬁnity ETA-agonist like ET-3
induces contractile responses. It is unlikely that these observations
result from a failure of synthesis, as methods of synthesis used were
identical to those of the biologically active Leu7ET-1. In earlier work,
replacement in ET-1 of the amino acids at positions 6 or 7 by alanine
did not modify binding afﬁnity to ETA-receptors in microsomes (Tam
et al., 1994), nor did these substitutions alter constrictor activity
(Huggins et al., 1993). However, in the current study, Leu6 is replaced
by a tryptophan, which will have a greater impact on structure-
function of a small peptide. While endothelinergic peptides contain-
ing the combinations ‘Leu6 Met7’ for ET-1 and ‘Trp6 Leu7’ for ET-2
can bind and activate ETA-receptors, combination of tryptophan on
position 6 and methionine on position 7 leads to a marked loss of
binding afﬁnity, despite that these substitutions would not alter back-
bone conformation (Wallace and Janes, 1995). It remains to be deter-
mined what the consequences of this combination are for the
conformation and ﬂexibility of the agonist molecule (Lattig et al.,
2009) leading to the observed loss in biological activity.
Agonist-dependence (or probe-dependence) is one of themain prop-
erties of allosteric modulation of receptor function. Further exploration
of this mechanism in the endothelin ﬁeld may ultimately lead to the
development of ET-receptor antagonists that discriminate between
endogenous endothelins (orthosteric agonists) acting in different organs
or that becomemore efﬁcaciouswith increasing activity of the endothelin
axis (Christopoulos and Kenakin, 2002; Keov et al., 2011).
In conclusion, arterial smooth muscle ETA-receptors display
agonist-dependent properties, involving the roles of amino acids on
position 6 and 7 of the endothelin sequence. Agonist-dependent
pathologies may beneﬁt from the design of speciﬁc, agonist-selective
ET-receptor antagonists.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.Acknowledgments
This study was performed within the framework of Dutch Top
Institute Pharma, project T2-301 Renin Angiotensin System Blockade
beyond Angiotensin II.References
Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA
encoding an endothelin receptor. Nature 1990;348:730–2.
Bogoni G, Rizzi A, Calo G, Campobasso C, D'Orleans-Juste P, Regoli D. Characterization
of endothelin receptors in the human umbilical artery and vein. Br J Pharmacol
1996;119:1600–4.Braasch I, Volff JN, Schartl M. The endothelin system: evolution of vertebrate-speciﬁc
ligand–receptor interactions by three rounds of genome duplication. Mol Biol
Evol 2009;26:783–99.
Breu V, Hashido K, Broger C, Miyamoto C, Furuichi Y, Hayes A, et al. Separable binding
sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan
on human endothelin-A receptors. Eur J Biochem 1995;231:266–70.
Chiou WJ, Wessale JL, von Geldern T, Opgenorth TJ, Wu-Wong JR. 'Irreversible'
endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-
induced effects. J Cardiovasc Pharmacol 2000;36:S48–52.
Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing.
Pharmacol Rev 2002;54:323–74.
Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin
receptor nomenclature. Pharmacol Rev 2002;54:219–26.
De Mey JG, Compeer MG, Lemkens P, Meens MJ. ETA-receptor antagonists or allosteric
modulators? Trends Pharmacol Sci 2011;32:345–51.
Deng LY, Li JS, Schiffrin EL. Endothelin receptor subtypes in resistance arteries from
humans and rats. Cardiovasc Res 1995;29:532–5.
Donoso MV, Faundez H, Rosa G, Fournier A, Edvinsson L, Huidobro-Toro JP. Pharmaco-
logical characterization of the ETA receptor in the vascular smooth muscle compar-
ing its analogous distribution in the rat mesenteric artery and in the arterial
mesenteric bed. Peptides 1996;17:1145–53.
Hilal-Dandan R, Villegas S, Gonzalez A, Brunton LL. The quasi-irreversible nature of
endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol
Exp Ther 1997;281:267–73.
Huggins JP, Pelton JT, Miller RC. The structure and speciﬁcity of endothelin receptors:
their importance in physiology and medicine. Pharmacol Ther 1993;59:55-123.
Hynynen MM, Khalil RA. The vascular endothelin system in hypertension—recent
patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006;1:95-108.
Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, et al. Biological proﬁles
of highly potent novel endothelin antagonists selective for the ETA receptor. Life
Sci 1992;50:247–55.
Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, et al. Biochemical and phar-
macological proﬁle of a potent and selective endothelin B-receptor antagonist,
BQ-788. Proc Natl Acad Sci U S A 1994;91:4892–6.
Keov P, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled recep-
tors: a pharmacological perspective. Neuropharmacology 2011;60:24–35.
Ko C, Gieske MC, Al-Alem L, Hahn Y, Su W, Gong MC, et al. Endothelin-2 in ovarian
follicle rupture. Endocrinology 2006;147:1770–9.
Lattig J, Oksche A, Beyermann M, Rosenthal W, Krause G. Structural determinants for
selective recognition of peptide ligands for endothelin receptor subtypes ETA and
ETB. J Pept Sci 2009;15:479–91.
Levin ER. Endothelins. N Engl J Med 1995;333:356–63.
Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin
peptides in human blood vessels in vitro. Br J Pharmacol 1995;115:191–7.
Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004;25:219–24.
Meens MJ, Fazzi GE, van Zandvoort MA, De Mey JG. Calcitonin gene-related peptide se-
lectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance
arteries. J Pharmacol Exp Ther 2009;331:87–95.
MeensMJ, CompeerMG,Hackeng TM, van ZandvoortMA, Janssen BJ, DeMey JG. Stimuli of
sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP
and dissociation of ET-1/ET(A)-receptor complexes. PLoS One 2010;5:e10917.
Meens MJ, Mattheij NJ, Nelissen J, Lemkens P, Compeer MG, Janssen BJ, et al. Calcitonin
gene-related peptide terminates long-lasting vasopressor responses to endothelin
1 in vivo. Hypertension 2011;58:99-106.
Meidan R, Levy N. The ovarian endothelin network: an evolving story. Trends Endocrinol
Metab 2007;18:379–85.
Mihara S, Fujimoto M. Non-isopeptide-selective endothelin receptors in human Girardi
heart cells. Life Sci 1992;50:219–26.
Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990;70:
921–61.
Saeki T, Ihara M, Fukuroda T, Yamagiwa M, Yano M. [Ala1,3,11,15]endothelin-1 analogs
with ETB agonistic activity. Biochem Biophys Res Commun 1991;179:286–92.
Saito A, Shiba R, Yanagisawa M, Masaki T, Kimura S, Yamada K, et al. Endothelins: va-
soconstrictor effects and localization in canine cerebral arteries. Br J Pharmacol
1991;103:1129–35.
Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors.
Trends Pharmacol Sci 1992;13:103–8.
Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB. In situ neutralization in
Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difﬁcult
sequences. Int J Pept Protein Res 1992;40:180–93.
Takizawa S, Uchide T, Adur J, Kozakai T, Kotake-Nara E, Quan J, et al. Differential expression
of endothelin-2 along the mouse intestinal tract. J Mol Endocrinol 2005;35:201–9.
Tam JP, Liu W, Zhang JW, Galantino M, Bertolero F, Cristiani C, et al. Alanine scan of
endothelin: importance of aromatic residues. Peptides 1994;15:703–8.
Wallace BA, Janes RW. The crystal structure of human endothelin-1 and how it relates
to receptor binding. J Cardiovasc Pharmacol 1995;26(Suppl. 3):S250–3.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel
potent vasoconstrictor peptide produced by vascular endothelial cells. Nature
1988;332:411–5.
